

AllianzGI Health Sciences Fund - Class A

Category
Health

Investment Objective & Strategy

From the investment's prospectus

The investment seeks long-term capital appreciation.

The fund seeks to achieve its objective by normally investing at least 80% of its net assets (plus borrowings made for investment purposes) in health sciences-related companies. The portfolio manager considers health sciences-related companies to include companies that design, manufacture or sell products or services used for or in connection with healthcare, medicine or life sciences. The fund will invest primarily in common stocks and other equity securities.

Past name(s) : AllianzGI Wellness A.

Volatility and Risk

Volatility as of 09-30-20



Risk Measures as of 09-30-20	Port Avg	Rel S&P 500	Rel Cat
3 Yr Std Dev	15.72	0.89	0.77
3 Yr Beta	0.73	—	0.79

Principal Risks

Short Sale, Credit and Counterparty, Currency, Emerging Markets, Foreign Securities, Loss of Money, Not FDIC Insured, High Portfolio Turnover, Issuer, Market/Market Volatility, Equity Securities, Industry and Sector Investing, IPO, Restricted/Illiquid Securities, Derivatives, Leverage, Management, Small Cap


Important Information

Morningstar Investment Profiles must be accompanied by Morningstar Disclosure and Glossary.

Funds or their affiliates may pay compensation to Voya® affiliates offering a fund. Such compensation may be paid out of distribution, service and/or 12b-1 fees that are deducted from the fund's assets, and/or may be paid directly by the fund's affiliates. Any fees deducted from fund assets are discussed in the fund's prospectus and disclosed in the fund fact sheet. Because these fees are paid on an on-going basis, over time these fees will increase the cost of your investment and may cost you more than paying other types of sales charges. If offered through a retirement program, additional fees and expenses may be charged under that program. NOT A DEPOSIT. NOT FDIC INSURED. NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY. NOT GUARANTEED BY THE INSTITUTION. MAY GO DOWN IN VALUE.

Portfolio Analysis


Composition as of 08-31-20



Top 10 Holdings as of 08-31-20

Top 10 Holdings	% Assets
AstraZeneca PLC ADR	5.54
Roche Holding AG ADR	5.36
Bristol-Myers Squibb Company	4.91
Novartis AG ADR	4.66
Johnson & Johnson	3.69
Horizon Therapeutics PLC	3.67
Pfizer Inc	3.41
Medtronic PLC	3.36
Zoetis Inc Class A	3.20
UnitedHealth Group Inc	3.10

Morningstar Style Box™ as of 08-31-20



Morningstar Equity Sectors as of 08-31-20

Morningstar Equity Sectors	% Fund
Cyclical	1.71
Basic Materials	1.71
Consumer Cyclical	0.00
Financial Services	0.00
Real Estate	0.00
Sensitive	0.00
Communication Services	0.00
Energy	0.00
Industrials	0.00
Technology	0.00
Defensive	98.29
Consumer Defensive	0.00
Healthcare	98.29
Utilities	0.00

Operations

Gross Prosp Exp Ratio	1.47% of fund assets
Net Prosp Exp Ratio	1.47% of fund assets
Management Fee	1.20%
12b-1 Fee	0.25%
Other Fee	0.00%
Miscellaneous Fee(s)	0.02%
Fund Inception Date	02-05-02
Total Fund Assets (\$mil)	169.4
Annual Turnover Ratio %	91.00
Fund Family Name	Allianz Global Investors

Waiver Data	Type	Exp. Date	%
—	—	—	—

Portfolio Manager(s)

Peter Pirsch, CFA. Since 2018.
Christopher Chin. Since 2020.

Advisor	Allianz Global Investors U.S. LLC
Subadvisor	—

Notes